Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL321827 | 0.80 | LMNA (0.64) | LMNAKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL1119074 | 0.78 | LMNA (0.61) | LMNAKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL10383823 | 0.74 | TP53 (0.53) | LMNAALDH1A1TP53 | |
| SCHEMBL10583875 | 0.70 | LMNA (0.38) | LMNA | |
| SCHEMBL17271401 | 0.69 | LMNA (0.49) | LMNAKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL8033430 | 0.68 | LMNA (0.51) | LMNAKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL29850232 | 0.67 | LMNA (0.47) | LMNAALDH1A1 | |
| SCHEMBL30075719 | 0.65 | LMNA (0.45) | LMNAALDH1A1 | |
| SCHEMBL31509083 | 0.65 | LMNA (0.78) | LMNAKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL145409 | 0.64 | KMT2A (0.47) | LMNAKDM4EMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1942 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230414702-A1 | COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER | PEPKON SAS (FR) | 2023-12-28 | — | — | US | claimed |
| WO-2021054927-A2 | GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS | SOUTH DAKOTA BOARD OF REGENTS (US) | 2021-03-25 | — | — | WO | claimed |
| US-20200230128-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. | 2020-07-23 | — | — | US | claimed |
| US-20200048305-A1 | GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS | SOUTH DAKOTA BOARD OF REGENTS (US) | 2020-02-13 | — | — | US | claimed |
| US-10179109-B2 | Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates | CHARLESTON LABORATORIES, INC. (US) | 2019-01-15 | — | — | US | claimed |
| EP-3423041-A1 | PHARMACEUTICAL COMPOSITIONS | Charleston Laboratories, Inc. (US) | 2019-01-09 | — | — | EP | claimed |
| US-20180344728-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. | 2018-12-06 | — | — | US | claimed |
| WO-2018191584-A1 | NUTRITIONAL AND THERAPEUTIC SUPPLEMENT COMPOSITIONS | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-10-18 | — | — | WO | claimed |
| US-20170304327-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2017-10-26 | — | — | US | claimed |
| US-9789105-B2 | Pharmaceutical compositions | LOCL PHARMA, INC. (US) | 2017-10-17 | — | — | US | claimed |
| WO-2012116277-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. (US) | 2012-08-30 | — | — | WO | claimed |
| US-20120201888-A1 | Pharmaceutical Compositions | CHARLESTON LABORATORIES, INC. (US) | 2012-08-09 | — | — | US | claimed |
| EP-2240022-A2 | PHARMACEUTICAL COMPOSITIONS | Charleston Laboratories, Inc. (US) | 2010-10-20 | — | — | EP | claimed |
| WO-2009089494-A2 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. (US) | 2009-07-16 | — | — | WO | claimed |
| US-20090175939-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. (US) | 2009-07-09 | — | — | US | claimed |
| WO-2006127024-A1 | REAGENTS AND METHODS FOR LABELING TERMINAL OLEFINS | EISAI CO. LTD. (JP) | 2006-11-30 | — | — | WO | claimed |
| US-20060045846-A1 | Reagents and methods for labeling terminal olefins | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-03-02 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048305-A1 | GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS | GSTK1, GSTO1, GSTM2 | LMNA 3751/4885KDM4E 4520/4885MEN1 1607/4885 |
| US-20170304327-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, GPR18 | LMNA 3561/4885KDM4E 2570/4885MEN1 3858/4885 |
| US-20060045846-A1 | Reagents and methods for labeling terminal olefins | EEF2, RNF168, REL | LMNA 2369/4885KDM4E 2980/4885MEN1 2020/4885 |
| US-20230414702-A1 | COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER | VIP, RNASE1, ABCB11 | LMNA 4237/4885KDM4E 4000/4885MEN1 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.